CLEVELAND, Sept. 22, 2016 /PRNewswire/ --ViewRay, Inc. (Nasdaq: VRAY), makers of the world's first and only clinical MRI-guided radiation therapy system, announced today that the company's MRIdian System and MRIdian Linac technology will be featured at the Annual Meeting of the American Society for Radiation Oncology (ASTRO), to be held September 25-28, 2016 in Boston.

MRI-guided radiation therapy continues to be a topic of significant interest, as reflected by the 18 MRIdian clinical presentations and posters accepted as part of ASTRO's Scientific Sessions. These presentations will be given by MRIdian users from Washington University and Siteman Cancer Center at Barnes-Jewish Hospital (Washington University); University of California, Los Angeles Health System and Jonsson Comprehensive Cancer Center (UCLA); and The University of Wisconsin Carbone Cancer Center (University of Wisconsin).

Eleven of the Scientific Session presentations will focus on MRIdian's adaptive capabilities, which enable clinicians to adapt treatment in real-time to changes and movement in a patient's anatomy, providing truly personalized medicine. ViewRay's integrated software designed for real-time treatment adaptation has enabled more than 600 on-table adaptive treatments to date. Other Scientific Session presentations will cover MRIdian benefits across a number of clinical indications including lymphoma, head and neck, abdominal, bladder, breast, gastric, pancreatic and prostate cancers.
MRIdian Linac technology will also be highlighted at the conference as part of ASTRO's Scientific Sessions. Researchers from Washington University will highlight a presentation titled "The design and implementation of a novel compact linac-based MRI guided radiation therapy (MR-IGRT) system" and researchers from UCLA will highlight a presentation titled, "The physics of a novel compact linear accelerator–based magnetic resonance imaging–guided radiation therapy system."

Earlier this week, ViewRay announced that the company had received CE Mark approval for the MRIdian Linac and had submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its MRIdian Linac technology. MRIdian Linac is available for sale and clinical use in Europe; however, in the United States, the technology is available for non-clinical research use only at this time.

"This is an exciting ASTRO for ViewRay, having recently received Japanese and Chinese regulatory approval for MRIdian, secured CE Mark approval for MRIdian Linac, and submitted our 510(k) application for the MRIdian Linac technology to the FDA," said Chris A. Raanes, president and chief executive officer of ViewRay. "We now look forward to presentations featuring MRIdian clinical experience and MRIdian Linac technology research by leading institutions at ASTRO."

Rad Oncology Homepage